<p>全球市場正在應對複雜的局面，美國股指在波動的經濟信號和勞動市場數據中經歷了混合走勢。在這種情況下，識別有前景的投資機會可能具有挑戰性，但對於那些尋求低成本增長潛力的投資者來説，便宜股仍然提供了引人注目的可能性。儘管 “便宜股” 這個術語可能顯得過時，這些較小或較新的公司在強大的財務支持和穩健的基本面下，往往呈現出獨特的機會。</p>
<h3>全球十大便宜股</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.17</td>
<td>A$102.84M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.61</td>
<td>HK$964.89M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>HSS Engineers Berhad (KLSE:HSSEB)</td>
<td>MYR0.63</td>
<td>MYR320.34M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.57</td>
<td>HK$2.15B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Deleum Berhad (KLSE:DELEUM)</td>
<td>MYR1.46</td>
<td>MYR586.27M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.17</td>
<td>SGD12.48B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Begbies Traynor Group (AIM:BEG)</td>
<td>£1.17</td>
<td>£186.24M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Deceuninck (ENXTBR:DECB)</td>
<td>€2.11</td>
<td>€291.65M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Netgem (ENXTPA:ALNTG)</td>
<td>€0.93</td>
<td>€31.36M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們全球便宜股篩選器中的 3,739 只股票的完整列表。</p>
<p>下面我們展示了一些經過篩選的股票。</p>
<h2>大名城控股 (SHSE:600094)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 大名城控股有限公司在中國房地產開發領域運營，市值為人民幣 73.9 億元。</p>
<p><strong>運營：</strong> 該公司在中國的運營收入為人民幣 45.3 億元。</p>
<p><strong>市值：</strong> 人民幣 73.9 億元</p>
<p>大名城控股有限公司在中國房地產領域運營，市值為人民幣 73.9 億元，2025 年上半年收入為人民幣 15.9 億元，較去年有所增長，但淨收入大幅下降至人民幣 3340 萬元。公司的財務健康狀況複雜；儘管在五年內將債務與股本比率降低至令人滿意的水平，但仍處於虧損狀態，過去五年年均收益下降 58%。儘管每週波動穩定，管理層和董事會經驗豐富，但在盈利能力和經營現金流的利息覆蓋方面仍面臨挑戰。</p>
<ul>
<li>點擊探索我們對大名城控股財務健康報告的詳細分析。</li>
<li>在這裏瞭解大名城控股的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2bb8ed32-3923-49c7-a724-802dfdf5817b/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2bb8ed32-3923-49c7-a724-802dfdf5817b/chart/debt-equity-history-analysis"/></p>
<p>SHSE:600094 債務與股本歷史及分析截至 2025 年 9 月</p>
<h2>中柱醫療控股有限公司 (SHSE:600568)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 中柱醫療控股有限公司專注於中國藥物的研究、開發、生產和銷售，市值為人民幣 36.9 億元。</p>
<p><strong>運營：</strong> 中柱醫療控股有限公司沒有具體的收入細分報告。</p>
<p><strong>市值：</strong> 人民幣 36.9 億元</p>
<p>中柱醫療控股有限公司市值為人民幣 36.9 億元，2025 年上半年收入為人民幣 3.0285 億元，較去年有所增長。儘管收入增加，淨虧損減少至人民幣 2414 萬元，但公司仍處於虧損狀態，過去五年年均虧損增長 23.9%。積極的一面是，公司無債務，短期資產（人民幣 12 億元）足以覆蓋其長期（人民幣 3740 萬元）和短期負債（人民幣 3.191 億元）。由於正向自由現金流趨勢，公司還受益於超過三年的穩定現金流。</p>
<ul>
<li>解鎖我們對中柱醫療控股有限公司股票分析的全面見解，詳見此財務健康報告。</li>
<li>查看中柱醫療控股有限公司的歷史業績報告，以瞭解其在往年中的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis"/></p>
<p>SHSE:600568 財務狀況分析截至 2025 年 9 月</p>
<h2>榮安地產有限公司 (SZSE:000517)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 榮安地產有限公司在中國開發和銷售房地產，市值為人民幣 62.4 億元。</p>
<p><strong>運營：</strong> 公司的收入完全來自其在中國的運營，總額為人民幣 259.8 億元。</p>
<p><strong>市值：</strong> 人民幣 62.4 億元</p>
<p>榮安地產有限公司面臨盈利下降的挑戰，2025 年上半年收入大幅下降至人民幣 39 億元，較去年同期的人民幣 138.8 億元大幅減少，淨收入從人民幣 4.6403 億元降至人民幣 3645 萬元。儘管處於虧損狀態，但其債務水平令人滿意，淨債務與股本比率為 10.3%，並且短期資產覆蓋超過其短期（人民幣 187 億元）和長期負債（人民幣 16 億元）。公司的董事會經驗豐富，但在持續的財務壓力下，其分紅記錄仍不穩定。</p>
<ul>
<li>點擊這裏訪問我們完整的財務健康分析報告，以瞭解榮安地產有限公司的動態。</li>
<li>使用我們的詳細歷史業績報告評估榮安地產有限公司的先前結果。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6b4612dc-7c91-4724-992e-729faa007fde/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6b4612dc-7c91-4724-992e-729faa007fde/chart/financial-position-analysis"/></p>
<p>SZSE:000517 財務狀況分析截至 2025 年 9 月</p>
<h2>關鍵要點</h2>
<ul>
<li>在這裏開始您的投資之旅，探索我們精選的 3,739 只全球便士股票。</li>
<li>對其他可能性感興趣？我們發現 18 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章不應被視為財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>

大名城

大名城B

榮安地產

<p>全球市場呈現出混合走勢，低價股成為潛在的投資機會。大名城、眾築醫療和榮安地產被強調為值得關注的低價股。大名城的市值為 73.9 億人民幣，但面臨盈利挑戰。眾築醫療的市值為 36.9 億人民幣，顯示出收入增長，但仍未盈利。榮安地產的估值為 62.4 億人民幣，報告顯示盈利和收入下降。儘管面臨挑戰，這些公司在當前市場環境中提供了獨特的投資可能性</p>

<p>Global markets have been navigating a complex landscape, with U.S. equity indexes experiencing mixed movements amid fluctuating economic signals and labor market data. In this context, identifying promising investment opportunities can be challenging, yet penny stocks continue to offer intriguing possibilities for those seeking growth potential at lower entry points. Though the term 'penny stock' might seem outdated, these smaller or newer companies often present unique opportunities when supported by strong financials and sound fundamentals.</p>
<div class="lb-trans"><p>全球市場正在應對複雜的局面，美國股指在波動的經濟信號和勞動市場數據中經歷了混合走勢。在這種情況下，識別有前景的投資機會可能具有挑戰性，但對於那些尋求低成本增長潛力的投資者來説，便宜股仍然提供了引人注目的可能性。儘管 “便宜股” 這個術語可能顯得過時，這些較小或較新的公司在強大的財務支持和穩健的基本面下，往往呈現出獨特的機會。</p>
</div><h3>Top 10 Penny Stocks Globally</h3>
<div class="lb-trans"><h3>全球十大便宜股</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.17</td>
<td>A$102.84M</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.61</td>
<td>HK$964.89M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>HSS Engineers Berhad (KLSE:HSSEB)</td>
<td>MYR0.63</td>
<td>MYR320.34M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.57</td>
<td>HK$2.15B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Deleum Berhad (KLSE:DELEUM)</td>
<td>MYR1.46</td>
<td>MYR586.27M</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.17</td>
<td>SGD12.48B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Begbies Traynor Group (AIM:BEG)</td>
<td>£1.17</td>
<td>£186.24M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Deceuninck (ENXTBR:DECB)</td>
<td>€2.11</td>
<td>€291.65M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Netgem (ENXTPA:ALNTG)</td>
<td>€0.93</td>
<td>€31.36M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.17</td>
<td>A$102.84M</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.61</td>
<td>HK$964.89M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>HSS Engineers Berhad (KLSE:HSSEB)</td>
<td>MYR0.63</td>
<td>MYR320.34M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.57</td>
<td>HK$2.15B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Angler Gaming (NGM:ANGL)</td>
<td>SEK3.60</td>
<td>SEK269.95M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Deleum Berhad (KLSE:DELEUM)</td>
<td>MYR1.46</td>
<td>MYR586.27M</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.17</td>
<td>SGD12.48B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Begbies Traynor Group (AIM:BEG)</td>
<td>£1.17</td>
<td>£186.24M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Deceuninck (ENXTBR:DECB)</td>
<td>€2.11</td>
<td>€291.65M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Netgem (ENXTPA:ALNTG)</td>
<td>€0.93</td>
<td>€31.36M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 3,739 stocks from our Global Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們全球便宜股篩選器中的 3,739 只股票的完整列表。</p>
</div><p>Underneath we present a selection of stocks filtered out by our screen.</p>
<div class="lb-trans"><p>下面我們展示了一些經過篩選的股票。</p>
</div><h2>Greattown Holdings (SHSE:600094)</h2>
<div class="lb-trans"><h2>大名城控股 (SHSE:600094)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Greattown Holdings Ltd. operates in the real estate development sector in China with a market capitalization of CN¥7.39 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 大名城控股有限公司在中國房地產開發領域運營，市值為人民幣 73.9 億元。</p>
</div><p><strong>Operations:</strong> The company generates revenue of CN¥4.53 billion from its operations within China.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司在中國的運營收入為人民幣 45.3 億元。</p>
</div><p><strong>Market Cap:</strong> CN¥7.39B</p>
<div class="lb-trans"><p><strong>市值：</strong> 人民幣 73.9 億元</p>
</div><p>Greattown Holdings Ltd. operates in China's real estate sector with a market cap of CN¥7.39 billion and generated revenue of CN¥1.59 billion for H1 2025, an increase from the previous year, though net income dropped significantly to CN¥33.4 million. The company's financial health is mixed; while it has reduced its debt-to-equity ratio over five years to a satisfactory level, it remains unprofitable with earnings declining by 58% annually over the past five years. Despite stable weekly volatility and experienced management and board teams, challenges persist in profitability and interest coverage by operating cash flow remains inadequate.</p>
<div class="lb-trans"><p>大名城控股有限公司在中國房地產領域運營，市值為人民幣 73.9 億元，2025 年上半年收入為人民幣 15.9 億元，較去年有所增長，但淨收入大幅下降至人民幣 3340 萬元。公司的財務健康狀況複雜；儘管在五年內將債務與股本比率降低至令人滿意的水平，但仍處於虧損狀態，過去五年年均收益下降 58%。儘管每週波動穩定，管理層和董事會經驗豐富，但在盈利能力和經營現金流的利息覆蓋方面仍面臨挑戰。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Greattown Holdings' financial health report.</li>
<li>Learn about Greattown Holdings' historical performance here.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們對大名城控股財務健康報告的詳細分析。</li>
<li>在這裏瞭解大名城控股的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2bb8ed32-3923-49c7-a724-802dfdf5817b/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/2bb8ed32-3923-49c7-a724-802dfdf5817b/chart/debt-equity-history-analysis"/></p>
<p>SHSE:600094 Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>SHSE:600094 債務與股本歷史及分析截至 2025 年 9 月</p>
</div><h2>Zhongzhu Healthcare HoldingLtd (SHSE:600568)</h2>
<div class="lb-trans"><h2>中柱醫療控股有限公司 (SHSE:600568)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Zhongzhu Healthcare Holding Co., Ltd focuses on the research, development, production, and sale of drugs in China, with a market cap of CN¥3.69 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 中柱醫療控股有限公司專注於中國藥物的研究、開發、生產和銷售，市值為人民幣 36.9 億元。</p>
</div><p><strong>Operations:</strong> There are no specific revenue segments reported for Zhongzhu Healthcare Holding Co., Ltd.</p>
<div class="lb-trans"><p><strong>運營：</strong> 中柱醫療控股有限公司沒有具體的收入細分報告。</p>
</div><p><strong>Market Cap:</strong> CN¥3.69B</p>
<div class="lb-trans"><p><strong>市值：</strong> 人民幣 36.9 億元</p>
</div><p>Zhongzhu Healthcare Holding Co., Ltd, with a market cap of CN¥3.69 billion, reported revenue of CN¥302.85 million for the first half of 2025, showing growth from the previous year. Despite this increase in revenue and a reduction in net loss to CN¥24.14 million, the company remains unprofitable with losses increasing over five years at 23.9% annually. Positively, it is debt-free and has sufficient short-term assets (CN¥1.2 billion) to cover both its long-term (CN¥37.4 million) and short-term liabilities (CN¥319.1 million). The company also benefits from a stable cash runway exceeding three years due to positive free cash flow trends.</p>
<div class="lb-trans"><p>中柱醫療控股有限公司市值為人民幣 36.9 億元，2025 年上半年收入為人民幣 3.0285 億元，較去年有所增長。儘管收入增加，淨虧損減少至人民幣 2414 萬元，但公司仍處於虧損狀態，過去五年年均虧損增長 23.9%。積極的一面是，公司無債務，短期資產（人民幣 12 億元）足以覆蓋其長期（人民幣 3740 萬元）和短期負債（人民幣 3.191 億元）。由於正向自由現金流趨勢，公司還受益於超過三年的穩定現金流。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Zhongzhu Healthcare HoldingLtd stock in this financial health report.</li>
<li>Examine Zhongzhu Healthcare HoldingLtd's past performance report to understand how it has performed in prior years.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對中柱醫療控股有限公司股票分析的全面見解，詳見此財務健康報告。</li>
<li>查看中柱醫療控股有限公司的歷史業績報告，以瞭解其在往年中的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/0a3cf580-900f-46c8-851b-02eca26e9944/chart/financial-position-analysis"/></p>
<p>SHSE:600568 Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>SHSE:600568 財務狀況分析截至 2025 年 9 月</p>
</div><h2>Rongan PropertyLtd (SZSE:000517)</h2>
<div class="lb-trans"><h2>榮安地產有限公司 (SZSE:000517)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Rongan Property Co., Ltd. develops and sells real estate properties in China, with a market cap of CN¥6.24 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 榮安地產有限公司在中國開發和銷售房地產，市值為人民幣 62.4 億元。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived entirely from its operations in China, amounting to CN¥25.98 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入完全來自其在中國的運營，總額為人民幣 259.8 億元。</p>
</div><p><strong>Market Cap:</strong> CN¥6.24B</p>
<div class="lb-trans"><p><strong>市值：</strong> 人民幣 62.4 億元</p>
</div><p>Rongan Property Co., Ltd. faces challenges with declining earnings, reporting a significant drop in revenue to CN¥3.90 billion for the first half of 2025 from CN¥13.88 billion a year prior, and net income falling to CN¥36.45 million from CN¥464.03 million. Despite being unprofitable, it maintains satisfactory debt levels with a net debt to equity ratio of 10.3% and has strong short-term asset coverage exceeding both its short-term (CN¥18.7 billion) and long-term liabilities (CN¥1.6 billion). The company's board is experienced, though its dividend track record remains unstable amidst ongoing financial pressures.</p>
<div class="lb-trans"><p>榮安地產有限公司面臨盈利下降的挑戰，2025 年上半年收入大幅下降至人民幣 39 億元，較去年同期的人民幣 138.8 億元大幅減少，淨收入從人民幣 4.6403 億元降至人民幣 3645 萬元。儘管處於虧損狀態，但其債務水平令人滿意，淨債務與股本比率為 10.3%，並且短期資產覆蓋超過其短期（人民幣 187 億元）和長期負債（人民幣 16 億元）。公司的董事會經驗豐富，但在持續的財務壓力下，其分紅記錄仍不穩定。</p>
</div><ul>
<li>Click here and access our complete financial health analysis report to understand the dynamics of Rongan PropertyLtd.</li>
<li>Assess Rongan PropertyLtd's previous results with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的財務健康分析報告，以瞭解榮安地產有限公司的動態。</li>
<li>使用我們的詳細歷史業績報告評估榮安地產有限公司的先前結果。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6b4612dc-7c91-4724-992e-729faa007fde/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/6b4612dc-7c91-4724-992e-729faa007fde/chart/financial-position-analysis"/></p>
<p>SZSE:000517 Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:000517 財務狀況分析截至 2025 年 9 月</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Embark on your investment journey to our 3,739 Global Penny Stocks selection here.</li>
<li>Interested In Other Possibilities? We've found 18 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏開始您的投資之旅，探索我們精選的 3,739 只全球便士股票。</li>
<li>對其他可能性感興趣？我們發現 18 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章不應被視為財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div>

全球便士股票：GREATTOWN 控股及另外兩個值得關注